We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Sophiris Targets Prostate Cancer With Modified Biologic

Interviews

Executive Summary

Nearly 140,000 men each year are diagnosed with localized prostate cancer, and the common treatment is radical - surgical removal of the prostate or whole organ radiation. Sophiris Bio is a San Diego-based biotech developing topsalysin for the focal treatment of localized prostate cancer, and may spare the organ from such massive collateral damage. Speaking at the Biotech Showcase, Sophiris CEO Randall Woods explained to Scrip how topsalysin works and how he is looking to continue clinical development of the biologic, in both localized prostate cancer and benign prostatic hyperplasia.